Butantan-DV
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT05710224 | Feb 2023 → Jan 2024 | dengue disease | Butantan Institute | Completed | No outcome recorded |
| Phase 2 | NCT01696422 | Oct 2013 → Apr 2016 | dengue disease | Butantan Institute | Unknown | No outcome recorded |
| Phase 33 trials · 1 met primary | ||||||
| Phase 3 | NCT06973772 | Mar → Jul 2027 expected | chikungunya, dengue disease | Butantan Institute | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07712926 | Feb 2027 → Feb 2028 expected | dengue disease | Butantan Institute | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT02406729 | Feb 2016 → Jul 2021 | dengue disease | Butantan Institute | Unknown | Met primary |
| Phase 41 trial | ||||||
| Phase 4 | NCT07087912 | Mar 2026 → Dec 2027 expected | Takayasu arteritis, antiphospholipid syndrome, granulomatosis with polyangiitis, idiopathic inflammatory myopathy +6 | University of Sao Paulo General Hospital | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2022-12-16 | Merck Sharp & Dohme LLC | Results MSD Collaborator Instituto Butantan Announces Results from Its Phase 3 Vaccine Candidate Trial for the Prevention of Dengue Disease msd.com ↗
We are working with Instituto Butantan to conduct a detailed analysis of these results in order to determine next steps for our own dengue vaccine candidate (V181). |
| 2022-12-16 | Merck Sharp & Dohme LLC | Results Merck Collaborator Instituto Butantan Announces Results from Its Phase 3 Vaccine Candidate Trial for the Prevention of Dengue Disease merck.com ↗ |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-12-16 | Merck Sharp & Dohme LLC | MSD Collaborator Instituto Butantan Announces Results from Its Phase 3 Vaccine Candidate Trial for the Prevention of Dengue Disease msd.com ↗ |
| 2022-12-16 | Merck Sharp & Dohme LLC | Merck Collaborator Instituto Butantan Announces Results from Its Phase 3 Vaccine Candidate Trial for the Prevention of Dengue Disease merck.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Butantan-DV | “V181 and Butantan-Dengue Vaccine (Butantan-DV) are independently developed, single-dose, quadrivalent dengue vaccines based on the same attenuated parental strains.” PMID 42383822 ↗ Jul 20265“Butantan-Dengue Vaccine (Butantan-DV) is an investigational, single-dose, live, attenuated, tetravalent vaccine against dengue disease” PMID 38294972 ↗ Feb 2024 “A single 0.5 mL dose of the live attenuated tetravalent dengue vaccine (Butantan-DV), administered subcutaneously on Day 1” NCT07087912 ↗ “the live attenuated tetravalent (LAT) Butantan DENV vaccine (Butantan-DV)” PMID 35837409 ↗ Jun 2022 |
| Known as | Butantan-Dengue Vaccine | “Butantan-Dengue Vaccine (Butantan-DV) is an investigational, single-dose, live, attenuated, tetravalent vaccine against dengue disease, but data on its overall efficacy are needed.” PMID 38294972 ↗ Feb 20242“V181 and Butantan-Dengue Vaccine (Butantan-DV) are independently developed, single-dose, quadrivalent dengue vaccines based on the same attenuated parental strains.” PMID 42383822 ↗ Jul 2026 “Here we report the long-term safety and efficacy of Butantan dengue vaccine (Butantan-DV), a live, attenuated, tetravalent dengue vaccine” PMID 41781546 ↗ Mar 2026 |
| Known as | Butantan-DV (IB) | “Butantan-DV manufactured at the Instituto Butantan - Butantan-DV (IB), mean 10³ PFU (per dose), subcutaneously, in the deltoid region.” NCT07712926 ↗ |
| Known as | Butantan-DV (WuXi) | “Butantan-DV manufactured at the WuXi Biologics CRDMO - Butantan-DV (WuXi),mean 10³ PFU (per dose), subcutaneously, in the deltoid region.” NCT07712926 ↗ |
| Modality | Vaccine | “V181 and Butantan-Dengue Vaccine (Butantan-DV) are independently developed, single-dose, quadrivalent dengue vaccines based on the same attenuated parental strains.” PMID 42383822 ↗ Jul 2026 |
| Route | Subcutaneous | “Route:subcutaneous” NCT01696422 ↗ |